UP!
 |
|
|
Type
|
Public |
|---|---|
| Traded as |
|
| Industry | Medical products |
| Founded | 1985 |
| Headquarters | Marlborough, Massachusetts, U.S. |
|
Key people
|
Stephen P. MacMillan President and CEO |
| Revenue | US$ 2.83 billion (2016) |
|
Operating income
|
US$ 0.5 billion (2016) |
|
Net income
|
US$ 0.3 billion (2016) |
|
Number of employees
|
~5,300 |
| Website | www.hologic.com |
Hologic, Inc. is a developer, manufacturer and supplier of diagnostic products, medical imaging systems and surgical products. The Company’s core business units focus on diagnostics, breast health, gynecological surgical, and skeletal health. Its major products include the Selenia Dimension mammography system, the Discovery and Horizon bone densitometers, the NovaSure endometrial ablation device, the ThinPrep pap test, and the Aptima, Cervista, and Prodesse diagnostic assays. While historically the Company was focused on women's health, expansion into the molecular diagnostics space has resulted in the Company's rebranding from "The Women's Health Company" to its current tagline, "The Science of Sure".
On May 20, 2007, Hologic announced a merger (via a cash and stock transaction) with the Cytyc Corporation to create a $10 billion women's healthcare company with over $1 billion in projected annual sales.
On April 30, 2012, Hologic announced a merger with Gen-Probe for about $3.72 billion by cash.
On February 14, 2017, it was announced that Hologic had acquired Cynosure, Inc., a leading manufacturer and distributor of aesthetic medical devices. The transaction was completed on March 22, 2017.
In late November 2013, activist investor Carl Icahn disclosed a 12.5% stake in the company. Subsequently, the company adopted a poison pill to prevent a hostile takeover. In negotiations with the Company's board of directors, two additional directors backed by Mr. Icahn were added to the board, each managing directors of Icahn holding companies. The directors relinquished their positions in March 2016; by April 2016, Icahn's share in the Company had fallen below 5%.
| Period | Date | Adjusted Actuals EPS | GAAP EPS |
|---|---|---|---|
| Q1 2023 | 2023-02-01 | 1.07 | 1.07 |
| Q4 2022 | 2022-10-31 | 0.82 | 0.82 |
| Q3 2022 | 2022-07-27 | 0.95 | 0.95 |
| Q2 2022 | 2022-04-27 | 2.07 | 2.07 |
| Q1 2022 | 2022-02-02 | 2.17 | 2.17 |
| Q4 2021 | 2021-11-01 | 1.61 | 1.61 |
| Q3 2021 | 2021-07-28 | 1.33 | 1.33 |
| Q2 2021 | 2021-04-28 | 2.59 | 2.59 |
| Q1 2021 | 2021-01-27 | 2.86 | 2.86 |
| Q4 2020 | 2020-11-04 | 2.07 | 2.07 |
| 2016-07-10 | Reiterated Rating | Barclays PLC | Hold | $42.00 |
| 2016-06-22 | Reiterated Rating | Bank of America | Buy | |
| 2016-06-22 | Reiterated Rating | Bank of America Corp. | Buy | |
| 2016-06-21 | Reiterated Rating | Jefferies Group | Buy | $42.00 |
| 2016-06-04 | Reiterated Rating | Morgan Stanley | Hold | |
| 2016-04-29 | Reiterated Rating | Goldman Sachs | Conviction-Buy to Buy | $45.00 |
| 2016-04-29 | Reiterated Rating | Goldman Sachs Group Inc. | Conviction-Buy to Buy | $45.00 |
| 2016-04-28 | Downgrade | Needham & Company LLC | Buy to Hold | |
| 2016-04-28 | Reiterated Rating | Canaccord Genuity | Buy | |
| 2016-04-28 | Reiterated Rating | Leerink Swann | Buy | |
| 2016-03-28 | Reiterated Rating | Bank of America | Buy | $46.00 |
| 2016-03-23 | Boost Price Target | Goldman Sachs | $47.00 | |
| 2016-03-07 | Reiterated Rating | Canaccord Genuity | Buy | $45.00 |
| 2016-02-19 | Reiterated Rating | Canaccord Genuity | Buy | |
| 2016-02-17 | Reiterated Rating | Piper Jaffray | Neutral | $38.00 |
| 2016-02-17 | Reiterated Rating | Piper Jaffray Cos. | Neutral | $38.00 |
| 2016-02-04 | Reiterated Rating | Piper Jaffray | Hold | |
| 2016-01-31 | Reiterated Rating | William Blair | Outperform | |
| 2016-01-28 | Upgrade | Needham & Company LLC | Hold to Buy | $41.00 |
| 2016-01-28 | Reiterated Rating | Leerink Swann | Buy | $47.00 to $44.00 |
| 2016-01-28 | Reiterated Rating | JPMorgan Chase & Co. | Buy | |
| 2016-01-28 | Reiterated Rating | Jefferies Group | Buy | |
| 2016-01-28 | Reiterated Rating | BTIG Research | Buy | $43.00 |
| 2016-01-07 | Boost Price Target | Barclays | Equal Weight | $40.00 to $42.00 |
| 2016-01-07 | Boost Price Target | Barclays PLC | Equal Weight | $40.00 to $42.00 |
| 2015-12-22 | Lower Price Target | Goldman Sachs | $49.00 to $48.00 | |
| 2015-12-11 | Upgrade | Stifel Nicolaus | Hold to Buy | $45.00 to $45.00 |
| 2015-11-26 | Upgrade | JPMorgan Chase & Co. | Neutral to Outperform | |
| 2015-11-22 | Reiterated Rating | Needham & Company LLC | Hold | |
| 2015-11-05 | Reiterated Rating | Leerink Swann | Buy | $46.00 to $44.00 |
| 2015-11-05 | Reiterated Rating | Needham & Company LLC | Hold | |
| 2015-11-05 | Reiterated Rating | BTIG Research | Buy | $43.00 |
| 2015-11-05 | Reiterated Rating | Canaccord Genuity | Buy | $45.00 |
| 2015-10-26 | Initiated Coverage | Gabelli | Buy | $43.00 |
| 2015-10-26 | Upgrade | BTIG Research | Neutral to Buy | $43.00 |
| 2015-10-21 | Downgrade | Craig Hallum | Buy to Hold | $42.00 to $37.00 |
| 2015-10-20 | Reiterated Rating | William Blair | Buy | |
| 2015-09-18 | Reiterated Rating | Jefferies Group | Buy | $44.00 to $48.00 |
| 2015-09-16 | Reiterated Rating | Canaccord Genuity | Buy | |
| 2015-09-11 | Reiterated Rating | William Blair | Buy | |
| 2015-09-02 | Upgrade | Barclays | Underweight to Equal Weight | $40.00 |
| 2015-08-03 | Reiterated Rating | Argus | Buy | $43.00 to $52.00 |
| 2015-07-30 | Reiterated Rating | BTIG Research | Neutral | |
| 2015-07-30 | Reiterated Rating | Canaccord Genuity | Buy | $40.00 to $45.00 |
| 2015-07-30 | Boost Price Target | Barclays | Underweight | $31.00 to $40.00 |
| 2015-07-24 | Initiated Coverage | Bank of America | Buy | $43.00 |
| 2015-07-16 | Downgrade | BTIG Research | Buy to Neutral | |
| 2015-07-14 | Downgrade | Piper Jaffray | Overweight to Neutral | |
| 2015-07-13 | Reiterated Rating | Evercore Partners Inc. | Buy to Hold | |
| 2015-07-13 | Downgrade | Evercore ISI | Buy to Hold | $37.50 to $38.50 |
| 2015-07-01 | Boost Price Target | Cowen and Company | Market Perform | $35.00 to $40.00 |
| 2015-06-01 | Boost Price Target | Canaccord Genuity | Buy | $37.00 to $40.00 |
| 2015-05-07 | Reiterated Rating | Cowen and Company | Market Perform | $30.00 to $35.00 |
| 2015-05-04 | Reiterated Rating | BTIG Research | Buy | $36.00 |
| 2015-05-04 | Boost Price Target | Argus | Buy | $38.00 to $43.00 |
| 2015-04-30 | Reiterated Rating | Canaccord Genuity | Buy | $37.00 |
| 2015-04-30 | Boost Price Target | Barclays | Underweight | $26.00 to $31.00 |
| 2015-04-30 | Boost Price Target | Jefferies Group | Buy | $34.00 to $38.00 |
| 2015-03-25 | Boost Price Target | RBC Capital | Sector Perform | $31.00 to $32.00 |
| 2015-03-25 | Boost Price Target | Royal Bank Of Canada | Sector Perform | $31.00 to $32.00 |
| 2015-03-05 | Downgrade | Needham & Company LLC | Buy to Hold | |
| 2015-02-19 | Upgrade | Canaccord Genuity | Hold to Buy | $29.00 to $37.00 |
| 2015-02-04 | Boost Price Target | Argus | Buy | $34.00 to $38.00 |
| 2015-01-29 | Reiterated Rating | Canaccord Genuity | Hold | $29.00 |
| 2015-01-29 | Boost Price Target | JPMorgan Chase & Co. | Overweight | $31.00 to $32.00 |
| 2015-01-29 | Boost Price Target | Jefferies Group | Buy | $31.00 to $34.00 |
| 2015-01-29 | Boost Price Target | Needham & Company LLC | $33.00 | |
| 2015-01-20 | Upgrade | William Blair | Market Perform to Outperform | |
| 2015-01-08 | Upgrade | BTIG Research | Neutral to Buy | $32.00 |
| 2015-01-07 | Initiated Coverage | Barclays | Underweight | $24.00 |
| 2014-12-30 | Upgrade | Goldman Sachs | Buy | |
| 2014-12-18 | Upgrade | Goldman Sachs | Buy to Conviction-Buy | $30.00 to $33.00 |
| 2014-11-06 | Reiterated Rating | Jefferies Group | Buy | $30.00 to $31.00 |
| 2014-11-03 | Boost Price Target | Canaccord Genuity | Hold | $23.00 to $26.00 |
| 2014-10-27 | Upgrade | Craig Hallum | Hold to Buy | |
| 2014-09-22 | Upgrade | Piper Jaffray | Neutral to Overweight | |
| 2014-08-05 | Downgrade | Barrington Research | Outperform to Market Perform | |
| 2014-07-31 | Reiterated Rating | JPMorgan Chase & Co. | Overweight | $28.00 to $31.00 |
| 2014-07-31 | Reiterated Rating | SunTrust | R | $15.00 to $18.00 |
| 2014-07-31 | Reiterated Rating | SunTrust Banks Inc. | R | $15.00 to $18.00 |
| 2014-07-09 | Boost Price Target | Evercore ISI | $27.00 to $29.00 | |
| 2014-07-07 | Downgrade | BTIG Research | Buy to Neutral | |
| 2014-07-02 | Downgrade | Standpoint Research | Buy to Hold | |
| 2014-06-25 | Boost Price Target | Needham & Company LLC | Buy | $26.00 to $30.00 |
| 2014-05-12 | Boost Price Target | Argus | Buy | $27.00 to $31.00 |
| 2014-05-01 | Reiterated Rating | JPMorgan Chase & Co. | Overweight | $28.00 |
| 2014-05-01 | Boost Price Target | RBC Capital | $21.00 to $22.00 | |
| 2014-05-01 | Reiterated Rating | Needham & Company LLC | Buy | |
| 2014-05-01 | Boost Price Target | Evercore ISI | $24.50 to $25.00 | |
| 2014-05-01 | Boost Price Target | Jefferies Group | $24.00 to $26.00 | |
| 2014-04-24 | Initiated Coverage | BTIG Research | Buy | $26.00 |
| 2014-02-04 | Reiterated Rating | Cantor Fitzgerald | Buy | $21.00 |
| 2014-02-04 | Reiterated Rating | Evercore ISI | Buy | $24.50 |
| 2014-01-22 | Downgrade | Evercore ISI | Strong-Buy to Buy | |
| 2014-01-06 | Downgrade | Morgan Stanley | Overweight to Equal Weight | $22.00 |
| 2014-01-03 | Set Price Target | Goldman Sachs | $22.00 to $27.00 | |
| 2013-12-02 | Downgrade | Cowen and Company | Outperform to Market Perform | $25.50 to $24.00 |
| 2013-11-21 | Reiterated | ISI Group | Strong Buy | $24.50 to $26.50 |
| 2013-11-21 | Reiterated Rating | Needham & Company LLC | Buy | $26.00 |
| 2013-11-21 | Reiterated Rating | Cantor Fitzgerald | Hold | $19.00 |
| 2013-11-21 | Boost Price Target | Evercore ISI | Strong-Buy | $24.50 to $26.50 |
| 2013-11-12 | Lower Price Target | Jefferies Group | Buy | $26.00 to $24.00 |
| 2013-11-12 | Lower Price Target | Evercore ISI | Strong-Buy | $26.00 to $25.00 |
| 2013-11-12 | Lower Price Target | Cantor Fitzgerald | Hold | $21.00 to $19.00 |
| 2013-11-12 | Reiterated Rating | Citigroup Inc. | Neutral | $24.00 to $22.00 |
| 2013-11-12 | Reiterated Rating | SunTrust | Reduce | $17.00 to $15.00 |
| 2013-11-12 | Downgrade | Craig Hallum | Buy to Hold | $23.00 to $21.00 |
| 2013-11-12 | Downgrade | William Blair | Outperform to Market Perform | |
| 2013-11-12 | Downgrade | Canaccord Genuity | Buy to Hold | $26.00 to $19.00 |
| 2013-11-12 | Downgrade | RBC Capital | Top Pick to Sector Perform | $25.00 to $21.00 |
| 2013-10-16 | Downgrade | Citigroup Inc. | Buy to Neutral | $24.00 |
| 2013-10-02 | Initiated | Needham | Buy | $26 |
| 2013-10-02 | Initiated Coverage | Needham & Company LLC | Buy | $26.00 |
| 2013-09-30 | Downgrade | Ned Davis Research | Neutral to Sell | |
| 2013-09-24 | Upgrade | ISI Group | Buy to Strong Buy | $25.50 |
| 2013-09-24 | Upgrade | Evercore ISI | Buy to Strong-Buy | $25.00 to $25.50 |
| 2013-05-07 | Downgrade | ISI Group | Strong Buy to Buy | $26 to $24 |
| 2013-04-10 | Initiated | Stifel | Hold | |
| 2013-02-05 | Reiterated | ISI Group | Strong Buy | $25.50 to $27 |
| 2012-05-01 | Reiterated | Cantor Fitzgerald | Hold | $18 to $20 |
| 2012-04-05 | Initiated | William Blair | Outperform | |
| 2011-12-05 | Resumed | Needham | Buy | $22 |
| 2011-07-29 | Upgrade | Barrington Research | Mkt Perform to Outperform | $24 |
| 2016-07-10 | Reiterated Rating | Barclays PLC | Hold | $42.00 |
| 2016-06-22 | Reiterated Rating | Bank of America | Buy | |
| 2016-06-22 | Reiterated Rating | Bank of America Corp. | Buy | |
| 2016-06-21 | Reiterated Rating | Jefferies Group | Buy | $42.00 |
| 2016-06-04 | Reiterated Rating | Morgan Stanley | Hold |
There is presents forecasts of rating agencies and recommendations for investors about this ticker
In HOLX 462 funds of 2213 total. Show all
| Fund name | Ticker shares |
|---|---|
| Vanguard Group, Inc | 28.42M |
| BlackRock Inc. | 23.40M |
| STATE STREET CORP | 11.55M |
| BlackRock Institutional Trust Company, N.A. | 7.82M |
| PRICE T ROWE ASSOCIATES INC /MD/ | 7.25M |
| BlackRock Fund Advisors | 6.18M |
| MACQUARIE GROUP LTD | 5.85M |
| GEODE CAPITAL MANAGEMENT, LLC | 5.83M |
| WELLINGTON MANAGEMENT CO LLP | 4.69M |
| VICTORY CAPITAL MANAGEMENT INC | 4.27M |
| FMR LLC | 3.93M |
| PARNASSUS INVESTMENTS /CA | 3.75M |
| JPMORGAN CHASE & CO | 3.45M |
| Invesco Ltd. | 3.44M |
| BlackRock Group LTD | 3.30M |
| Name Relationship | Total Shares | Holding stocks |
|---|---|---|
| ICAHN CARL C | 10.14% (28154879) | ARII / CVI / CVRR / ENZN / FDML / FRX / HAIN / HLF / HOLX / HTZ / IEP / LNG / MENT / NAV / NUAN / PBY / RNF / SD / TTWO / VGR / VLTC / WBMD / WCIC / XRX / |
| MACMILLAN STEPHEN P President and CEO | 0.51% (1422675) | ALR / BSX / HOLX / |
| MUIR GLENN P Executive VP and CFO | 0.29% (815306) | HOLX / RGEN / RWLK / |
| CASCELLA ROBERT CEO and President | 0.14% (400655) | HOLX / |
| STEIN JAY A Chief Technical Officer | 0.07% (201648) | HOLX / |
| CRAWFORD SALLY | 0.06% (154444) | EPRS / EXAS / HOLX / PODD / UAM / |
| McMahon Robert W. Chief Financial Officer | 0.04% (112596) | HOLX / |
| Compton Eric B. COO | 0.04% (107560) | HOLX / |
| HULL CARL SVP and GM of Diagnostics | 0.02% (61674) | HOLX / |
| Mills Roger D. SVP & GM, Service & Operations | 0.02% (58823) | HOLX / |
| LEAMING NANCY | 0.02% (55595) | BIIB / EDGW / HOLX / |
| Harding David SVP, International | 0.02% (53645) | HOLX / OVAS / TTOO / |
| Griffin John M. General Counsel | 0.02% (52174) | HOLX / |
| SOLTANI PETER SVP & GM, Women\'s Health | 0.02% (42625) | HOLX / |
| WILSON WAYNE | 0.02% (42487) | ARIA / CNSL / EDGW / FRP / HOLX / |
| Valenti Peter J. III Division Pres., Breast Health | 0.01% (39096) | HOLX / |
| Stamoulis Christiana | 0.01% (35039) | HOLX / |
| Levy Lawrence M | 0.01% (32615) | HOLX / |
| West Thomas A. Div President & GM, Diagnostic | 0.01% (28906) | HOLX / |
| ULLIAN ELAINE | 0.01% (27302) | HOLX / TMO / VRTX / |
| Brady David J SVP, Human Resources | 0.01% (25677) | HOLX / |
| GARRETT SCOTT T | 0.01% (22828) | HOLX / |
| Bebo Allison P SVP, Human Resources | 0.01% (21406) | HOLX / |
| Dockendorff Charles J | 0.01% (17776) | BSX / COV / HAE / HOLX / |
| Casey Mark J SVP, CAO & General Counsel | 0.01% (14725) | HOLX / IDRA / MNK / |
UM